Amazing the confidence you have in pointing to a 127 patient phase 2, while the 4x larger phase 3, discussed at great length in the same "gotcha" document you link to, was successful at providing the four month statistically significant survival extension for ADVANCED prostate cancer. And the confidence as well you have at thinking one can ignore a $billion of expenses of DNDN just because they were debt financed, absolutely mind-boggling.